-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NA53ML58PuWlcz1M/QY8SzojFgFjTyWFIG1ej1tWSkoZ7cBmiptunM0vFYISrbS1 xk8AS40TNRfEzBvxBW6u7A== 0001140361-08-011720.txt : 20080509 0001140361-08-011720.hdr.sgml : 20080509 20080509132517 ACCESSION NUMBER: 0001140361-08-011720 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080508 FILED AS OF DATE: 20080509 DATE AS OF CHANGE: 20080509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOKAY KEVIN G CENTRAL INDEX KEY: 0001211256 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14879 FILM NUMBER: 08817389 MAIL ADDRESS: STREET 1: GLAXOSMITHKLINE STREET 2: THREE FRANKLIN PLAZA, 1600 VINE STREET CITY: PHILADELPHIA STATE: PA ZIP: 19102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOGEN CORP CENTRAL INDEX KEY: 0000725058 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222322400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 650 COLLEGE RD EAST STE 3100 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099878200 MAIL ADDRESS: STREET 1: 650 COLLEGE RD EAST STE 3100 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc1.xml FORM 4 X0202 4 2008-05-08 1 0000725058 CYTOGEN CORP CYTO 0001211256 LOKAY KEVIN G C/O CYTOGEN CORPORATION 650 COLLEGE ROAD EAST, STE 3100 PRINCETON NJ 08540 1 0 0 0 Common Stock 2008-05-08 4 D 0 11836 D 0 D Common Stock 2008-05-08 4 D 0 185439 D 0 D Options to Purchase Common Stock 0.57 2008-05-08 4 D 0 400000 D Common Stock 400000 0 D Options to Purchase Common Stock 0.57 2008-05-08 4 D 0 100000 D Common Stock 100000 0 D These shares include shares previously issued pursuant to Cytogen Corporation's 2005 Employee Stock Purchase Plan. These shares were converted into the right to receive the merger consideration, as provided in the Agreement and Plan of Merger, dated March 10, 2008, by and among Cytogen Corporation, EUSA Pharma, Inc. and EUSA Pharma (USA), Inc. (the "Merger") of $0.62 per share. This restricted stock became fully vested and exercisable upon consummation of the Merger. In connection with the Merger, these shares were cancelled in exchange for the right to receive $0.62 per share. This option was cancelled in connection with the Merger in exchange for the right to receive the excess of the exercise price over the per share merger consideration of $0.62, for a total payment of $20,000. This option was cancelled in connection with the Merger in exchange for the right to receive the excess of the exercise price over the per share merger consideration of $0.62, for a total payment of $5,000. /s/ Kevin G. Lokay 2008-05-09 -----END PRIVACY-ENHANCED MESSAGE-----